PCSK9 concentrations in different stages of subclinical atherosclerosis and their relationship with inflammation

被引:1
|
作者
Toth, Stefan [1 ]
Olexa, Peter [1 ]
Hertelyova, Zdenka [2 ]
Stefanic, Peter [3 ]
Kopolovets, Ivan [3 ]
Berek, Peter [3 ]
Filip, Vladimir [4 ]
Chakravarty, Ryan [1 ]
Siroka, Monika [5 ]
Pella, Daniel [6 ,7 ]
机构
[1] Pavol Jozef Safarik Univ, Air Force Mil Hosp, Fac Med, Dept Gerontol & Geriatr, Murgasova 1, Kosice 04086, Slovakia
[2] Pavol Jozef Safarik Univ, Dept Expt Med, Fac Med, Trieda SNP 1, Kosice 04190, Slovakia
[3] East Slovak Inst Cardiovasc Dis, Dept Vasc Surg, Ondavska 8, Kosice 04011, Slovakia
[4] Pavol Jozef Safarik Univ, Louis Pasteur Univ Hosp, Dept Orthopaed & Traumatol Locomotory Apparat, Trieda SNP 1, Kosice 04190, Slovakia
[5] Pavol Jozef Safarik Univ, Fac Med, Dept Med & Clin Biochem, Trieda SNP 1, Kosice 04190, Slovakia
[6] Pavol Jozef Safarik Univ, Fac Med, Dept Cardiol 2, Ondavska 8, Kosice 04011, Slovakia
[7] East Slovak Inst Cardiovasc Dis, Ondavska 8, Kosice 04011, Slovakia
来源
OPEN CHEMISTRY | 2020年 / 18卷 / 01期
关键词
PCSK9; inflammation; atherosclerosis; plaque; initiation; INTIMA-MEDIA THICKNESS; PLASMA PCSK9; RISK; EVOLOCUMAB; STIFFNESS; DISEASE;
D O I
10.1515/chem-2020-0147
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The aim of this study was to detect the concentrations of PCSK9 in various subclinical stages of atherosclerosis and to highlight its relationship with inflammation. One hundred and fifty-nine healthy patients were divided into three groups, based on the extent of atherosclerotic changes in the carotid artery: a group without identifiable atherosclerosis, cIMT(>)(75 parts per thousand) and an asymptomatic plaque group. The PCSK9 was measured by ELISA and hsCRP by the immunoturbidimetric method. Vascular changes were identified by a carotid ultrasound. PCSK9 was elevated, when comparing the healthy group with the cIMT(>75 parts per thousand) group; however, no significant increase was detected between cIMT(>75 parts per thousand) and the asymptomatic plaque group. A positive linear correlation of the PCSK9 concentration and atherosclerotic changes was found; however, after the re-analysis in each group, this correlation persisted only in the group with still normal values. Additionally, a significant linear correlation was found between the PCSK9 concentrations and lipid parameters. However, no significant association was found with hsCRP. PCSK9 was found to be elevated only in cIMT(>75 parts per thousand), but not in the later plaque stage. A linear correlation of PCSK9 values was detected only in the group with still reference values. Based on this fact, we assumed the direct linear role of PCSK9 in initiating atherosclerosis; however, in the later phases, the relationship, which highlights other risk factors such as inflammation, is not linear.
引用
收藏
页码:1011 / 1019
页数:9
相关论文
共 50 条
  • [1] Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidemias
    Vlachopoulos, Charalambos
    Koutagiar, Iosif
    Terentes-Printzios, Dimitrios
    Skoumas, Ioannis
    Rigatou, Angeliki
    Miliou, Antigoni
    Skliros, Alexandros-Nikitas
    Pantou, Stavroula
    Filis, Kostantinos
    Tousoulis, Dimitrios
    HELLENIC JOURNAL OF CARDIOLOGY, 2019, 60 (02) : 124 - 128
  • [2] PCSK9: A novel inflammation modulator in atherosclerosis?
    Tang, Zhi-Han
    Li, Tao-Hua
    Peng, Juan
    Zheng, Jie
    Li, Ting-Ting
    Liu, Lu-Shan
    Jiang, Zhi-Sheng
    Zheng, Xi-Long
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (03) : 2345 - 2355
  • [3] Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
    Punch, Emily
    Klein, Justus
    Diaba-Nuhoho, Patrick
    Morawietz, Henning
    Garelnabi, Mahdi
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (03):
  • [4] Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis-The IMPROVE Study
    Coggi, Daniela
    Frigerio, Beatrice
    Bonomi, Alice
    Ruscica, Massimiliano
    Ferri, Nicola
    Sansaro, Daniela
    Ravani, Alessio
    Ferrante, Palma
    Damigella, Manuela
    Veglia, Fabrizio
    Capra, Nicolo
    Lupo, Maria Giovanna
    Macchi, Chiara
    Savonen, Kai
    Silveira, Angela
    Kurl, Sudhir
    Giral, Philippe
    Pirro, Matteo
    Strawbridge, Rona Juliette
    Gigante, Bruna
    Smit, Andries Jan
    Tremoli, Elena
    Amato, Mauro
    Baldassarre, Damiano
    BIOMEDICINES, 2021, 9 (07)
  • [5] Increased PCSK9 associated with cIMT in AS: A useful marker for subclinical atherosclerosis in patients with ankylosing spondylitis
    Karakoyun, Ahmet
    Akkubak, Yasemin
    Goktepe, Mevlut Hakan
    Yilmaz, Pinar Diydem
    Kadiyoran, Cengiz
    Ogul, Mustafa
    Kucuk, Adem
    ARCHIVES OF RHEUMATOLOGY, 2024, 39 (04) : 652 - 661
  • [6] PCSK9: A potential regulator of apoE/apoER2 against inflammation in atherosclerosis?
    Bai, Xue-qin
    Peng, Juan
    Wang, Mei-mei
    Xiao, Jun
    Xiang, Qiong
    Ren, Zhong
    Wen, Hong-yan
    Jiang, Zhi-sheng
    Tang, Zhi-han
    Liu, Lu-shan
    CLINICA CHIMICA ACTA, 2018, 483 : 192 - 196
  • [7] An Update on the Role of PCSK9 in Atherosclerosis
    Yurtseven, Ece
    Ural, Dilek
    Baysal, Kemal
    Tokgozoglu, Lale
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2020, 27 (09) : 909 - 918
  • [8] PCSK9 and Atherosclerosis - Lipids and Beyond
    Shapiro, Michael D.
    Fazio, Sergio
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2017, 24 (05) : 462 - 472
  • [9] Reply to: "PCSK9 antagonists and inflammation"
    Tang, Zhi-Han
    Liu, Lu-Shan
    Zheng, Xi-Long
    Jiang, Zhi-Sheng
    ATHEROSCLEROSIS, 2018, 268 : 237 - 238
  • [10] PCSK9: A key factor modulating atherosclerosis
    Li, Sha
    Li, Jian-Jun
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2015, 22 (03) : 221 - 230